Gene info: ID 1173

Gene: AP2M1

GENE ID: 1173

Synonyms: AP50|CLAPM1|mu2

Description: adaptor related protein complex 2 subunit mu 1

Gene type: protein-coding

Location: 3q27.1

dbXrefs: Ensembl:ENSG00000161203 MIM:601024 Vega:OTTHUMG00000156822 UniprotKB:Q96CW1

RefSeq: NC_000003.12

Retrived from: SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: AD

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 7.155e-1 (AD) 4.736e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs13262	chr3:184183601 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg05573306	chr3:183894763	AP2M1	Promoter	7.019e-4	Alcohol use disorders	26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MDH2	0.98
OTUB1	0.98
ATP6V1E1	0.978
UCHL1	0.977
SAE1	0.975
PPP1R11	0.975
DCTN2	0.975
GOT2	0.975
USP5	0.974
RNF187	0.973

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.755
OR4F29	-0.721
KCNJ15	-0.346
CXCR2	-0.341
MTRNR2L6	-0.337
TFPI2	-0.335
IL18RAP	-0.335
REST	-0.332
CSAG1	-0.332
MTRNR2L10	-0.326

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C472791	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in decreased expression of AP2M1 mRNA	12958071
C498826	4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide	[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of AP2M1 mRNA	28786057
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of AP2M1 gene	27153756
D000638	Amiodarone	Amiodarone affects the expression of AP2M1 mRNA	19483382
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of AP2M1 mRNA	16483693
C006632	arsenic trioxide	[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of AP2M1 mRNA	28786057
D001280	Atrazine	Atrazine results in increased expression of AP2M1 mRNA	22378314
D001553	Benzbromarone	Benzbromarone affects the expression of AP2M1 mRNA	19483382
C006780	bisphenol A	bisphenol A affects the expression of AP2M1 mRNA	25181051
C099555	CD 437	CD 437 results in decreased expression of AP2M1 mRNA	12958071
D002994	Clofibrate	Clofibrate affects the expression of AP2M1 mRNA	19483382
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of AP2M1 mRNA	19376846
D003042	Cocaine	Cocaine results in increased expression of AP2M1 protein	25100957
D016572	Cyclosporine	Cyclosporine results in decreased expression of AP2M1 mRNA	25562108\|2798913
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of AP2M1 mRNA	17942748
D005001	Ethionine	Ethionine affects the expression of AP2M1 mRNA	19483382
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of AP2M1 gene	27776689
D005485	Flutamide	Flutamide results in decreased expression of AP2M1 mRNA	24793618
D005978	Glutathione	Glutathione deficiency results in increased expression of AP2M1 mRNA	15345336
D007657	Ketone Bodies	Ketone Bodies results in increased expression of AP2M1 mRNA	16807920
D007854	Lead	Lead results in decreased expression of AP2M1 mRNA	19921347
C008261	lead acetate	lead acetate results in decreased expression of AP2M1 mRNA	21891863
D008731	Methoxychlor	Methoxychlor results in increased methylation of AP2M1 gene	23303685
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of AP2M1 protein	26558463
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of AP2M1 protein	26558463
D015741	Metribolone	Metribolone promotes the reaction [NDRG1 protein binds to AP2M1 protein]	17220478
C523184	mocetinostat	mocetinostat results in decreased expression of AP2M1 mRNA	27255383
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of AP2M1 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of AP2M1 mRNA"	25554681
C051752	nefazodone	nefazodone results in increased expression of AP2M1 mRNA	24136188
D005996	Nitroglycerin	Nitroglycerin results in increased expression of AP2M1 mRNA	12102619
D009853	Omeprazole	Omeprazole affects the expression of AP2M1 mRNA	19483382
D010634	Phenobarbital	Phenobarbital affects the expression of AP2M1 mRNA	19159669
C014153	pirimiphos methyl	pirimiphos methyl results in decreased expression of AP2M1 mRNA	27845199
C006253	pirinixic acid	pirinixic acid affects the expression of AP2M1 mRNA	19483382
D011441	Propylthiouracil	Propylthiouracil affects the expression of AP2M1 mRNA	19483382
D012524	Sarin	Sarin results in increased expression of AP2M1 protein	25842371
D012643	Selenium	Selenium results in increased expression of AP2M1 mRNA	19244175
C017947	sodium arsenite	sodium arsenite results in decreased expression of AP2M1 mRNA	20308225
D013629	Tamoxifen	Tamoxifen results in increased expression of AP2M1 mRNA	17555576
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of AP2M1 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of AP2M1 mRNA	17942748
D019284	Thapsigargin	Thapsigargin results in decreased expression of AP2M1 protein	24648495
D013853	Thioacetamide	Thioacetamide affects the expression of AP2M1 mRNA	19483382
D014050	Toluene	Toluene affects the expression of AP2M1 mRNA	21827849
D014118	Toxins, Biological	"Toxins, Biological affects the expression of AP2M1 mRNA"	19682533
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid affects the expression of AP2M1 mRNA	18422935
C406224	valdecoxib	valdecoxib results in increased expression of AP2M1 mRNA	24136188
D014635	Valproic Acid	Valproic Acid results in increased expression of AP2M1 mRNA	23179753
D014635	Valproic Acid	Valproic Acid affects the expression of AP2M1 mRNA	17292431
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of AP2M1 gene	25560391
D014810	Vitamin E	Vitamin E results in increased expression of AP2M1 mRNA	19244175

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005048	signal sequence binding	-	IDA	8918456 9171339
GO:0005215	transporter activity	-	TAS	7989329 8595912
GO:0005515	protein binding	-	IPI	10910768 12032142 16189514 19419997 20029029 22916011 24189400 24603492 25107275
GO:0008289	lipid binding	-	IEA	-
GO:0035615	clathrin adaptor activity	contributes_to	TAS	12121421
GO:0044325	ion channel binding	-	IPI	23529131
GO:0050750	low-density lipoprotein particle receptor binding	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006886	intracellular protein transport	-	IEA	-
GO:0016050	vesicle organization	-	IMP	25898166
GO:0019886	antigen processing and presentation of exogenous peptide antigen via MHC class II	-	TAS	-
GO:0031623	receptor internalization	-	IMP	25898166
GO:0032802	low-density lipoprotein particle receptor catabolic process	-	TAS	-
GO:0034383	low-density lipoprotein particle clearance	-	TAS	-
GO:0048013	ephrin receptor signaling pathway	-	TAS	-
GO:0050690	regulation of defense response to virus by virus	-	TAS	-
GO:0060071	Wnt signaling pathway, planar cell polarity pathway	-	TAS	-
GO:0061024	membrane organization	-	TAS	-
GO:0072583	clathrin-dependent endocytosis	-	TAS	12121421
GO:0097494	regulation of vesicle size	-	IMP	25898166
GO:1903077	negative regulation of protein localization to plasma membrane	-	IMP	19581412

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005765	lysosomal membrane	-	TAS	-
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IDA	-
GO:0005886	plasma membrane	-	TAS	-
GO:0030122	AP-2 adaptor complex	-	TAS	12121421
GO:0030666	endocytic vesicle membrane	-	TAS	-
GO:0030669	clathrin-coated endocytic vesicle membrane	-	TAS	-
GO:0036020	endolysosome membrane	-	TAS	-
GO:0045334	clathrin-coated endocytic vesicle	-	NAS	25898166
GO:0070062	extracellular exosome	-	HDA	19056867

KEGG ID	KEGG Term
hsa04144	Endocytosis
hsa05016	Huntington's disease

Reactome ID	Reactome Term	Evidence
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1266738	Developmental Biology	IEA
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-157858	Gap junction trafficking and regulation	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-162906	HIV Infection	TAS
R-HSA-162909	Host Interactions of HIV factors	TAS
R-HSA-1643685	Disease	TAS
R-HSA-164938	Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	TAS
R-HSA-164939	Nef mediated downregulation of CD28 cell surface expression	TAS
R-HSA-164952	The role of Nef in HIV-1 replication and disease pathogenesis	TAS
R-HSA-166520	Signaling by NTRKs	IEA
R-HSA-166520	Signaling by NTRKs	TAS
R-HSA-167590	Nef Mediated CD4 Down-regulation	TAS
R-HSA-168256	Immune System	TAS
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	TAS
R-HSA-177504	Retrograde neurotrophin signalling	IEA
R-HSA-177504	Retrograde neurotrophin signalling	TAS
R-HSA-182218	Nef Mediated CD8 Down-regulation	TAS
R-HSA-187037	Signaling by NTRK1 (TRKA)	IEA
R-HSA-187037	Signaling by NTRK1 (TRKA)	TAS
R-HSA-190828	Gap junction trafficking	TAS
R-HSA-190873	Gap junction degradation	TAS
R-HSA-195721	Signaling by WNT	TAS
R-HSA-196025	Formation of annular gap junctions	TAS
R-HSA-199991	Membrane Trafficking	TAS
R-HSA-2132295	MHC class II antigen presentation	TAS
R-HSA-2682334	EPH-Ephrin signaling	TAS
R-HSA-373760	L1CAM interactions	TAS
R-HSA-373760	L1CAM interactions	IEA
R-HSA-382551	Transport of small molecules	TAS
R-HSA-3858494	Beta-catenin independent WNT signaling	TAS
R-HSA-3928665	EPH-ephrin mediated repulsion of cells	TAS
R-HSA-399719	Trafficking of AMPA receptors	TAS
R-HSA-399721	Glutamate binding, activation of AMPA receptors and synaptic plasticity	TAS
R-HSA-4086400	PCP/CE pathway	TAS
R-HSA-416993	Trafficking of GluR2-containing AMPA receptors	TAS
R-HSA-422475	Axon guidance	TAS
R-HSA-422475	Axon guidance	IEA
R-HSA-437239	Recycling pathway of L1	TAS
R-HSA-437239	Recycling pathway of L1	IEA
R-HSA-5099900	WNT5A-dependent internalization of FZD4	TAS
R-HSA-5140745	WNT5A-dependent internalization of FZD2, FZD5 and ROR2	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-5663205	Infectious disease	TAS
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis	TAS
R-HSA-8856828	Clathrin-mediated endocytosis	TAS
R-HSA-8866427	VLDLR internalisation and degradation	TAS
R-HSA-8964038	LDL clearance	TAS
R-HSA-8964043	Plasma lipoprotein clearance	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal